These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 32131468)
1. Identifying Novel ATX Inhibitors via Combinatory Virtual Screening Using Crystallography-Derived Pharmacophore Modelling, Docking Study, and QSAR Analysis. Ren JX; Zhang RT; Zhang H Molecules; 2020 Mar; 25(5):. PubMed ID: 32131468 [TBL] [Abstract][Full Text] [Related]
2. In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer. Ren JX; Li CP; Zhou XL; Cao XS; Xie Y J Biomol Struct Dyn; 2018 Jul; 36(9):2424-2435. PubMed ID: 28714799 [TBL] [Abstract][Full Text] [Related]
3. Identification of novel VP35 inhibitors: Virtual screening driven new scaffolds. Ren JX; Zhang RT; Zhang H; Cao XS; Liu LK; Xie Y Biomed Pharmacother; 2016 Dec; 84():199-207. PubMed ID: 27657828 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents. Patel P; Singh A; Patel VK; Jain DK; Veerasamy R; Rajak H Comb Chem High Throughput Screen; 2016; 19(9):735-751. PubMed ID: 27487787 [TBL] [Abstract][Full Text] [Related]
5. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking. Lee YH; Yi GS Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555 [TBL] [Abstract][Full Text] [Related]
6. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds. Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044 [TBL] [Abstract][Full Text] [Related]
7. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations. Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912 [TBL] [Abstract][Full Text] [Related]
8. Ligand-based pharmacophore modelling and virtual screening for the identification of amyloid-beta diagnostic molecules. Marondedze EF; Govender KK; Govender PP J Mol Graph Model; 2020 Dec; 101():107711. PubMed ID: 32898834 [TBL] [Abstract][Full Text] [Related]
9. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing. Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574 [TBL] [Abstract][Full Text] [Related]
10. Identification of potential tumour-associated carbonic anhydrase isozyme IX inhibitors: atom-based 3D-QSAR modelling, pharmacophore-based virtual screening and molecular docking studies. Kumar A; Rathi E; Kini SG J Biomol Struct Dyn; 2020 Apr; 38(7):2156-2170. PubMed ID: 31179854 [TBL] [Abstract][Full Text] [Related]
11. Virtual screening of B-Raf kinase inhibitors: A combination of pharmacophore modelling, molecular docking, 3D-QSAR model and binding free energy calculation studies. Zhang W; Qiu KX; Yu F; Xie XG; Zhang SQ; Chen YJ; Xie HD Comput Biol Chem; 2017 Oct; 70():186-190. PubMed ID: 28892749 [TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Musoev A; Numonov S; You Z; Gao H Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858 [TBL] [Abstract][Full Text] [Related]
13. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR. El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392 [TBL] [Abstract][Full Text] [Related]
14. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine. Chaudhari HK; Pahelkar A Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898 [TBL] [Abstract][Full Text] [Related]
15. Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors. Shah BM; Modi P; Trivedi P J Biomol Struct Dyn; 2021 Apr; 39(6):2021-2043. PubMed ID: 32242496 [TBL] [Abstract][Full Text] [Related]
16. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum. Kumari M; Chandra S; Tiwari N; Subbarao N BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744 [TBL] [Abstract][Full Text] [Related]
18. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening. Chaudhari P; Bari S Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560 [TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity. Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621 [TBL] [Abstract][Full Text] [Related]
20. Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors. Lanka G; Begum D; Banerjee S; Adhikari N; P Y; Ghosh B Comput Biol Med; 2023 Nov; 166():107481. PubMed ID: 37741229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]